Access’ President and CEO, Jeffrey B. Davis recently conducted a Q&A with OutsideIn Research, a small-cap equity research firm. The interview was published in two parts, the first of which is below:
Q: Tell us about Access Pharmaceuticals, its history and its focus.
Jeffrey B. Davis: Access Pharma is a Dallas-based biotechnology company that’s been around for many years, but underwent a re-engineering and re-focusing roughly three years ago. At that time, the Company refocused on its oncology assets, and divested of its dermatology and wound healing assets. The three year “re-engineering” effort has been a great success, resulting in its first FDA-approved therapy, MuGard, significant development in its two Phase 2 assets, ProLindac and Thiarabine, and great progress in its Cobalamin Oral Drug Delivery and Targeted Drug Delivery platforms. Over that period, the Board of Directors was revamped, new management expertise brought in, a new strategy put in place, and many partnerships being signed. I believe that it positions Access Pharmaceuticals very well for success, and I think it’s a great time for the investment community to take a fresh look at our Company.
Read more »
DALLAS, TX and NEW YORK, NY July 29, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, today announced that it will host a conference call at 11:00 a.m. EDT on August 3rd, to provide an update on the Company’s strategy and activities surrounding the official launch its lead product, MuGard in North America. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
Read more »
DALLAS, TX and NEW YORK, NY July 27, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, today announced its e-marketing partner, iMedicor (OTCBB: VMCI) commenced the initial phase of a multi-channel marketing program for MuGard. iMedicor’s two-pronged marketing approach involves leveraging its direct sales channel through Direct Medical Solutions (DMS) and its online pharma marketing portal to further support Access’ ongoing commercial launch efforts for its lead product. The initial phase of the marketing program for MuGard includes a targeted sampling program to DMS’ physician network.
Read more »
Agreement Provides Multi-level Distribution Of Lead Product, Including Inventory In Over 30 Top Metro Areas
DALLAS, TX and NEW YORK, NY July 20, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip (Nasdaq: BIOS) for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. The agreement aligns the Company with comprehensive access to BioScrip’s nationwide distribution platform and the ability to leverage the company’s extensive physician relationships, 110 BioScrip specialty pharmacies, mail distribution capability and diversified payor network.
Read more »
Company To Update Investors On Activities Surrounding Commercial Launch Of Lead Product
DALLAS, TX and NEW YORK, NY June 28, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), President and CEO Jeffrey B. Davis will present at the One Med Forum: Emerging Company Finance Conference on Wednesday, June 30th at 9:20 AM ET. The conference is being held at the Roosevelt Hotel in New York City.
Davis will provide an overview of Access’ clinical development programs and update investors on commercialization launch activities for its lead product, MuGard – a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Access Pharmaceuticals, Inc. is gearing up for the North American commercial launch set for late summer.
Read more »
MuGard Clinical Experience Reflects Delayed Onset, Significant Reduction in Pain, and Ease-of-Use in the Management of Oral Mucositis and Stomatitis
DALLAS, TX and New York, NY June 24, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy. To date, clinical experience shows that MuGard provides significant clinical benefit and is effective in the management of oral mucositis/stomatitis as well as other conditions of the oral cavity involving erythema. Key points from the poster include:
Read more »
Company Provides Update on MuGard™ Commercial Launch Activities
DALLAS, TX and New York, NY June 22, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is sponsoring an Oral Mucositis Symposium today for researchers and health care professionals attending the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. later this week. In an effort to further educate and build awareness of the debilitating side effect of anticancer treatments, the Oral Mucositis (OM) Symposium will feature leading industry experts covering various topics concerning the disease, from pathogenesis and clinical factors to prevention and management of oral mucositis. The OM Symposium is being held from 8:30 AM – 5:30 PM at the British Columbia Cancer Research Centre in Vancouver.
Read more »
Initiative Provides Full-Course MuGard Supportive Care Therapy for 500 Cancer Patients
DALLAS, TX and NEW YORK, NY June 15, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has initiated a broad-scale MuGard Centers-of-Excellence Sampling Program with leading oncology networks for its lead product, MuGard, a FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
Read more »
DALLAS, TX and New York, NY April 21, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma’s FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
Read more »
DALLAS, TX and NEW YORK, NY April 15, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it is collaborating with leading expert in oral mucositis (“OM”), Stephen T. Sonis, DMD, DMSc, Chief of the Division of Oral Medicine at the Dana Farber Cancer Institute and Program Director for Supportive Cancer Care at Clinical Assistance Programs, LLC (“CAP”), to further advance ongoing marketing and reimbursement efforts for MuGard. Together with Dr. Sonis, Access Pharma will develop a program to generate additional clinical data to further support the Company’s marketing and reimbursement initiatives surrounding the U.S. commercial launch of its lead product, MuGard – a FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Dr. Sonis will be the primary author on a study protocol aimed at obtaining specific data that will help further broaden the indication for MuGard and support reimbursement efforts geared towards enhancing payer uptake of MuGard. Any MuGard studies will run parallel with the product’s ongoing commercialization efforts.
Read more »
Tweet
Digg!
Del.icio.us
Follow Us
Accesspharma: RT @